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Abstract 
The COVID-19 pandemic resulted in the cancellation or postponement of traditional face-to-face 
scientific conferences, necessitating a rapid change in the way new discoveries in cancer were 
shared with the cancer research community. Here I present personal reflections on the upsurge of 






Springtime usually heralds the start of the conference season for academics and many of us look 
forward to visiting different destinations to engage with colleagues from across the world to learn 
about the latest findings in cancer research, spend time discussing these in social settings and 
forging new collaborations. This year has been different; the identification of a cluster of pneumonia 
cases in Wuhan, China, in December 2019, caused by a novel coronavirus (2019-nCoV) 1, resulted in 
the rapid escalation of the COVID-19 pandemic. Consequently, national and international travel was 
suspended, leading to the cancellation or postponement of traditional face-to-face scientific 
conferences, necessitating a swift change in the way discoveries in cancer research were delivered. 
Technological innovations in the digital space were embraced, offering the opportunity to provide 
conferences ‘virtually’, with delegates participating from their own homes. 
 
One of the first cancer conferences to be affected by the pandemic was the American Association for 
Cancer Research (AACR) annual conference, scheduled to take April 24-29 in San Diego, California. A 
stalwart in the cancer research calendar, this was initially rescheduled for August 2020 as a 
traditional face-to-face conference, but the emerging pandemic and associated public health risk 
resulted in the organisers moving swiftly to replace this with a two-part virtual conference. The first 
part, AACR I, was delivered April 27-28, partly coinciding with the dates of the original conference, 
with AACR II scheduled for late June.  Although the pandemic has brought many aspects of daily life 
to a standstill, people continue to receive cancer diagnoses and require treatment and it was fitting 
that the AACR I plenary session was dedicated to discussing how the COVID-19 pandemic had 
impacted on the treatment and care of cancer patients featuring speakers from areas which had 
been, at the time of the conference, most badly affected by the pandemic, including Wuhan, China; 




AACR I focused predominantly on clinical trials and drug discovery, providing a mechanism for the 
cancer research community to report the results of clinical trials which may benefit patient 
outcomes, avoiding unnecessary delays in reporting these as a result of the pandemic. This was 
realised with the efficacy and safety data of a MET inhibitor, capmatinib (Tabrecta), in treating non–
small cell lung cancer patients with METex14 skipping mutations, reported in the lung cancer clinical 
plenary session 2, resulting in its recent approval from the Food and Drug Administration (FDA). 
 
The overall content of the AACR I virtual  conference was broadly in line with what we have come to 
expect from a regular face-to-face conference, including oral and poster presentations, and was the 
trailblazer for virtual cancer meetings, attracting over 61,000 registrants from 140 countries 2.  
Others followed. In May, close to 10,000 delegates joined the European Society for Medical 
Oncology (ESMO) Virtual Breast Cancer Meeting, with all abstracts originally accepted for 
presentation at the face-to-face meeting remaining in the virtual programme. This multidisciplinary 
meeting brought together scientists and clinicians engaged in breast cancer research, and like AACR 
I, the keynote lecture focused on COVID-19, specifically how this had impacted on breast cancer 
treatment and clinical trials. The American Society of Clinical Oncology (ASCO) annual conference 
also went virtual with, clinical trials were given priority. In Europe, the 2020 Congress of the 
European Association for Cancer Research (EACR), originally scheduled for Torino, Italy, has been 
replaced with a virtual event. However, not all cancer conferences have gone virtual. The National 
Cancer Research Institute (NCRI) annual conference, a 3-day event which provides a forum to 
showcase the latest advances in cancer research in the UK, was cancelled. Although not being 
offered in a fully virtual format, the NCRI are providing a series of weekly webinars to keep 




So far, virtual conferences have been free to attend, requiring creation of an online account and 
password to gain access. This contrasts the often-expensive conference registration fees plus 
associated travel and accommodation costs that delegates need to meet from their research 
budgets. This might explain the impressive numbers of delegates achieved e.g. by AACR I and ESMO 
Breast Cancer which far exceed the numbers of delegates typically attending the equivalent face-to-
face event. Whether virtual events will continue to be free in the long term remains to be seen, as 
there as still costs associated with running these and dedicated events management companies are 
now offering virtual event platforms. Aside from financial benefits to delegates, virtual conferences 
are attractive to those with restricted ability for international travel e.g. those with young children or 
other caring responsibilities. Virtual conferences have also increased international reach to oncology 
stakeholders, allowing meeting registrants from across the globe to participate, either via live 
streaming or on demand to accommodate those in different time zones. 
 
Like traditional conferences, virtual conferences require considerable effort to put together; it’s not 
a case of simply putting together a few pre-recorded sessions, and some may be better resourced 
than others in their ability to deliver this. There have been some technical issues with IT and 
variability in the delivery of presentations, and even within conferences, some sessions have been 
hybrids of live delivery and pre-recorded presentations. In the case of the former, streaming has 
sometimes been an issue, although this may result from personal internet connectivity, beyond the 
control of the conference organisers. There were often unexpected delays between sessions, a time 
when one would normally be moving to another session held in an adjoining hall or using the time 
for networking or refreshment breaks. Session moderators were not always visible and the ability to 
ask questions “off the cuff” was lost with questions having to be typed into chat boxes with the 
moderator selecting which ones to ask, hence losing some of the spontaneity, reaction to body 
language and challenge associated with fielding face-to-face questions. However, we are still 
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learning the best ways to navigate this new virtual conference world. Best practice guidelines have 
recently been published to facilitate optimal scheduling and delivery of virtual conferences 3. 
 
Most virtual cancer conferences staged thus far have included all the features we have come to 
expect from face-to-face conferences, including satellite symposia, virtual exhibitions and pre-
recorded poster discussion sessions, delivered as short online presentations and late-breaking work. 
However, traditional poster sessions are, arguably, the biggest casualties of virtual conferences. 
Although we have become used to electronic poster boards at face-to-face conferences, the 
presenter of the poster is usually there to explain their work.  Virtual poster sessions are not the 
same; with no one around to talk you through the work, the interactive nature is lost. And for early 
careers researchers, the apprehension (and excitement!) we have all experienced of presenting our 
first poster at a conference and the prospect of having to field questions from experts in the field 
cannot be replicated in a virtual world.  
 
Input from patient advocates is also lost. These have been a welcome inclusion at cancer 
conferences in recent years, with their personal views and experiences injecting fresh perspectives 
into the cancer space, introducing a more patient-centric approach to clinical trials and, increasingly, 
shaping laboratory research 4. Most major cancer conferences now offer advocate bursaries giving 
recipients the opportunity to network with fellow advocates, clinicians, and scientists allowing 
bidirectional learning. This has been a very successful formula but something which is unlikely to be 
sustained in virtual settings, where the patient voice may not be heard. If virtual conferences are to 




For delegates, valuable networking opportunities are lost too, alongside the opportunity to turn to 
your neighbour in the audience to muse over a point made by a speaker spontaneously and catch up 
with colleagues and friends from overseas or strike up a conversation at a poster session. While 
some events have tried to address this, offering virtual networking using secure online chats or one-
on-one video calls, these were not the same as meeting in person. From a personal perspective 
attending AACR, ASCO, ESMO etc. from the home environment was a very different experience with 
the conference vibe missing.  
 
Is this the future for cancer conferences? In some respects the upsurge of virtual conferences is 
analogous to the explosion of MOOCs (Massive Open Online Courses) in the early 2010s. MOOCs 
became very popular in a short space of time and were seen as a mechanism of using the internet to 
bring a snapshot of higher education to those who may not otherwise have had this opportunity 5. At 
one stage MOOCs were perceived as the future of higher education, but with sustainability 
questioned 6, just as quickly as they became popular, their popularity waned. Once the pandemic 
eases and travel restrictions are relaxed, the same may apply to virtual conferences. It’s still early 
days so time will tell. 
 
Author’s contributions: VS conceived and wrote the article 
Conflict of interest: none 
Ethical approval and consent to participate: Not applicable 
Data availability: Not applicable 
Competing interests: None 




1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 
2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020; 395(10223): 497-
506; e-pub ahead of print 2020/01/24; doi 10.1016/S0140-6736(20)30183-5. 
2. https://www.abstractsonline.com/pp8/#!/9045/presentation/10786. 
3. Rubinger L, Gazendam A, Ekhtiari S, Nucci N, Payne A, Johal H et al. Maximizing virtual 
meetings and conferences: a review of best practices. International orthopaedics 2020: 1-6; 
e-pub ahead of print 2020/05/24; doi 10.1007/s00264-020-04615-9. 
4. Ciccarella A, Staley AC, Franco AT. Transforming research: engaging patient advocates at all 
stages of cancer research. Ann Transl Med 2018; 6(9): 167-167; doi 
10.21037/atm.2018.04.46. 
5. Liyanagunawardena TR, Williams SA. Massive open online courses on health and medicine: 
review. Journal of medical Internet research 2014; 16(8): e191; e-pub ahead of print 
2014/08/16; doi 10.2196/jmir.3439. 
6. Walsh K. Massive Open Online Courses on Health and Medicine: Will They Be Sustainable? 
Journal of medical Internet research 2014; 16(8): e197; doi 10.2196/jmir.3798. 
 
